Is HTFL a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Heartflow (HTFL) rests on Case volume compounding faster than revenue: Global case growth of ~67% in Q1 2026 outran the ~41% revenue increase, which means adoption is running ahead of pricing. The bear case rests on competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. Analysts covering it publish targets from $39.00 to $64.00 against a $54.98 price, so even the professionals disagree by 50% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Heartflow, founded in 2007 and based in Mountain View, California, sells analysis rather than hardware. A hospital or imaging center uploads a single coronary computed tomography angiography (CCTA) study, and the Heartflow One platform returns three products built off that one scan: FFRCT Analysis, which computes fractional flow reserve non-invasively to say whether a narrowing is actually restricting blood flow; RoadMap Analysis, which measures stenosis severity vessel by vessel; and Plaque Analysis, which quantifies plaque volume and composition. Each analysis is billed as a case, so revenue scales with scan volume rather than with device placements. Roughly ~93% of revenue comes from the United States, where hospitals bill FFRCT under its own CPT code (75580) and the 2021 ACC/AHA chest pain guideline made CCTA a first-line test for intermediate-risk stable chest pain. The numbers describe a company buying market adoption. Trailing twelve-month revenue is ~$212M. Revenue rose ~41% in the March 2026 quarter to ~$52.6M, with global case volume up ~67%, which is faster than revenue and tells you average revenue per case is drifting down as newer products and international accounts mix in. GAAP gross margin reached ~80% (from ~75%), but the FY2025 net loss was ~$117M and the Q1 2026 adjusted EBITDA loss was ~$14M. Management raised FY2026 guidance in May to ~$228M to ~$232M, held then against ~$255M of cash and investments at March 31, 2026. The second quarter accelerated. Revenue reached ~$64.1M, up ~47.6% year over year, the net loss narrowed to ~$15.7M from ~$27.4M in Q1, and the per-share loss of ~$0.07 was well ahead of the ~$0.13 consensus. Analysts now model ~$249M of 2026 revenue, above the range management set in May. In late August an independent, government-funded trial presented at the ESC congress reported that an FFRCT-guided pathway cut unnecessary invasive heart procedures by nearly half. The stock responded: it closed at $49.53 on October 16, 2026, up ~71% year to date and ~95% over three months, for a ~$4.3B market capitalization and a revenue multiple near ~20x. Executives including the CEO and CFO sold shares in September as the stock set a 52-week high of ~$54.32, and Q3 results are expected around November 11, 2026.

The bull case: what would have to be true for $64.00

The most optimistic published target on HTFL is $64.00, +16.4% from the $54.98 price as of November 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Case volume compounding faster than revenue

Global case growth of ~67% in Q1 2026 outran the ~41% revenue increase, which means adoption is running ahead of pricing. That gap is the growth engine and the margin question at the same time: more scans per account raises utilization on a fixed software cost base, but a lower average price per case means revenue growth lags volume growth. Q2 2026 revenue growth of ~47.6% was faster than Q1's ~41%, which suggests pricing drag has not yet capped the top line.

2. Plaque Analysis as the second product on the same scan

Plaque Analysis attaches to a CCTA the account has already ordered, so incremental revenue arrives with almost no incremental acquisition cost. Management raised the 2026 outlook for this line to ~$19M to ~$21M after it ran ahead of plan, making it the clearest near-term evidence that Heartflow can sell more than one analysis per study.

3. Guidelines and reimbursement carrying the demand

Heartflow's growth is downstream of clinical guidance rather than direct-to-patient marketing. The 2021 ACC/AHA chest pain guideline elevated CCTA for intermediate-risk stable chest pain, the PRECISE trial (2023) showed an FFRCT-guided pathway cut invasive catheterizations that found no obstructive disease, and FFRCT has a dedicated CPT code with Medicare outpatient payment. Reimbursement for plaque quantification is earlier in that same process. The late-August ESC data from an independent, government-funded trial, which showed FFRCT nearly halving unnecessary invasive procedures, adds outside evidence to that case.

4. Software economics with a widening cash runway question

At ~80% gross margin, each additional case drops most of its revenue to contribution, which is why the adjusted EBITDA loss is shrinking while spending continues. With ~$255M of cash and investments at March 31, 2026 and a quarterly net loss that fell to ~$15.7M in Q2 (trailing free cash outflow is ~$34M), the arithmetic gives several years of runway on current burn, provided the loss keeps narrowing rather than expanding with the asymptomatic-screening trial program.

The bear case: what would have to be true for $39.00

The most pessimistic published target is $39.00, -29.1% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Heartflow is worth if the risks below bite instead of the drivers above.

Competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. Reimbursement is the entire revenue model, so a change to the FFRCT payment rate, a coverage restriction, or slow code assignment for plaque quantification would hit revenue directly rather than gradually. Roughly ~93% of revenue is United States concentration, which leaves the business exposed to one payer system. The company has never earned a profit, lost ~$117M in FY2025 and ~$118M over the trailing twelve months, and needs continued volume growth to reach breakeven before cash becomes a constraint. Finally, the $6B addressable-market expansion management describes depends on trials in asymptomatic populations that have not read out, and the stock's ~$20 to ~$54 52-week range shows how quickly the market repricing works in both directions. After a ~95% three-month gain the shares trade near ~20x trailing sales, above the ~$47 average analyst target, and a run of insider sales by the CEO, CFO and other insiders in September 2026 is a reminder that early holders are taking liquidity.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HTFL already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on HTFL

8 analysts cover HTFL, with an average target of $50.50 (-8.1% against $54.98) and a split of 8 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HTFL forecast and price target page.

How is HTFL valued? (as of October 2026)

Price

$54.98

Market cap

$4.78B

Forward P/E

-203.01

Price / book

17.04

52-week range

$20.13 to $60.56

Snapshot for HTFL as of November 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$212M
Q2 2026 revenue: ~$64.1M, up ~47.6% year over year
Gross margin (TTM): ~80%
Net loss: ~$118M TTM; Q2 2026 ~$15.7M (EPS -$0.07 vs -$0.13 est.)
Price to sales: ~20x trailing on a ~$4.3B market cap ($49.53, Oct 16, 2026)
2026 revenue: Guidance ~$228M to ~$232M (May); consensus ~$249M
Cash vs debt: ~$163M cash vs ~$27M debt (Yahoo, June 30, 2026)

There is no price-to-earnings figure because there are no earnings, so the market is valuing Heartflow on revenue: a market capitalization near ~$4.3B against ~$212M of trailing revenue works out to roughly ~20x sales, up from ~12x in August after the stock nearly doubled over three months. That multiple assumes growth stays well above 30% and gross margin holds near ~80%. The next data point is the Q3 2026 report expected around November 11, where consensus looks for ~$65.2M of revenue and a ~$0.10 per-share loss.

How do you decide if HTFL is a buy?

Whether HTFL is a buy is easier to judge through four narrower questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold HTFL indirectly through an index or sector ETF before adding more.

What would change your mind on HTFL

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Case volume compounding faster than revenue stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
Bear case breaks if: competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the HTFL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HTFL against your real portfolio and see your actual exposure before deciding.

Investing in Heartflow with AI

Connect the broker you already use and ask Walnut's AI how HTFL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does HTFL fit me?

FAQ

Is HTFL a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Case volume compounding faster than revenue, with revenue (ttm) at ~$212M. The bear case rests on competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. Analysts covering it are spread from $39.00 to $64.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell HTFL?

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $39.00, -29.1% from the $54.98 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for HTFL?

Case volume compounding faster than revenue. Global case growth of ~67% in Q1 2026 outran the ~41% revenue increase, which means adoption is running ahead of pricing. The most optimistic analyst target on HTFL is $64.00, +16.4% from the $54.98 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for HTFL?

What does Heartflow do?

Coronary CT analysis software (FFRCT, RoadMap, Plaque Analysis) sold to hospitals as a service rather than as imaging hardware.

What would have to change for HTFL to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Case volume compounding faster than revenue) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What is HTFL?

HTFL is the Nasdaq ticker for Heartflow, Inc., a Mountain View, California medical software company. Its Heartflow One platform uses AI and computational fluid dynamics to convert a single coronary CT scan into a personalized 3D model of the heart's arteries, then reports blood flow (FFRCT), stenosis severity and plaque volume and composition.

What exchange is HTFL listed on, and how do you buy it?

Heartflow trades on the Nasdaq under HTFL, so it is available through any US brokerage that offers Nasdaq-listed equities, including in fractional-share amounts at brokers that support them. It is a single-company position in medical technology, not a diversified healthcare fund, so position sizing carries the concentration.

Is Heartflow profitable?

No. Heartflow reported a ~$117M net loss for FY2025 and a ~$14M adjusted EBITDA loss in the March 2026 quarter. Gross margin is high at ~80%, so the losses come from sales, clinical and research spending rather than from the cost of delivering each analysis. The gap is narrowing: the second-quarter 2026 net loss was ~$15.7M, down from ~$27.4M in the first quarter, and the trailing net loss is ~$118M.

Walnut is informational, not investment advice, and gives no verdict on HTFL. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.